In total, 413 clinical isolates of Streptococcus pneumoniae were collected from four University laboratories in Sofia, Pleven, Plovdiv and Varna for the period of 2006-2008. 150 strains (36, 3%) of all 413 tested S. pneumoniae were erythromycin-resistant (ERSP). The most prevalence of ERSP were observed in children under 5 years (80.0%).
INTRODUCTION
Streptococcus pneumoniae is an important pathogen in many community-acquired respiratory infections such as bacterial sinusitis, otitis media, community acquired pneumonia and in more invasive infections like meningitis and bacteremia.
The pneumococcus is becoming increasingly resistant to a variety of antibiotics (7, 8) . Nowadays multiply resistant pneumococci that are resistant to penicillin, erythromycin, clindamycin, tetracycline, chloramphenicol and trimetoprimsulfametoxazol have been reported very often (2, 3) . The present study examined the in-vitro sus-ceptibility to macrolides of S. pneumoniae isolates from four main University hospitals in Bulgaria. The main aims were to deter-mine the frequency of resistance to macrolides in our country, and to investigate the mecha-nisms of macrolide resistance. Resistance seems to be associated mainly with efflux mechanisms, but nowadays target site modification by the erm(B) gene is more common.
Pneumococcal macrolide resistance can be caused by erm(B) (erythromycin ribosome methylase)-encoded methylation of a residue in the 23S rRNA (1) . Phenotypically, this results in the MLSB resistance phenotype, with resistance to all macrolides plus lincosamides and streptogramin B antibiotics. An alternative resistance mechanism involves mef (E) (macrolide efflux), resulting in M-type resistance to 14-and 15-membered macrolides, but not to 16-membered macrolides, lincosamides or streptogramin B antibiotics. The simultaneous presence of mef(E) and erm(B) has been reported also. Initial identification of isolates was done by test for optochin susceptibility as a primary identifica-tion method and if it was necessary, by another test such as bile solubility.
MATERIALS and METHODS

Bacterial isolates
Susceptibility testing
All macrolide resistant strains S.pneumoniae were tested both by Agar Dilution method and MIC testing for penicillin G, erythromycin and clindamycin on Mueller-Hinton agar (Oxoid, England) containing 5% sheep blood. Incubation (5% CO2) was for 24 h at 37°C.
Identification of resistance phenotypes
Resistance phenotypes were determined by triple disk test with erythromycin, clindamycin and rokitamycin (4) for all macrolide-resistance strains S.pneumoniae which have erythromycin susceptibility d" 20 mm. All isolates (0.5x McFarland standard) were tested on Mueller-Hinton agar (Oxoid, England) containing 5% sheep blood.
Serotyping. The pneumococci were serotyped by slide agglutination with factor-specific antisera (Statens Serum Institute, Copenhagen, Denmark) and observed by phase contrast microscopy (Binocular, Carl Zeiss). Pneumococcal diagnostic antisera are intended for identification and typing of pneumococci by means of the capsular reaction test. A positive reaction is the result of an in situ immunoprecipitation, leading to a change in the refractive index. In addition the bacteria agglutinate.
Molecular identification methods
The presence of erythromycin resistance genes erm(B) and mef(E) were identified by conventional PCR according to the method of Sutcliffe et al. (6) Following growth overnight on blood agar in 5 % CO2, single colonies were grown in 5 ml of Todd Hewitt Broth with Yeast extract (BBL,Becton,Dickinson and Company,) for 6 h, and this was followed by extraction of DNA. All erythromycin-resistant isolates were analysed further by PCR.
PCR buffers and DNA polymerase were supplied by Abgene,UK and all DNA primers were purchased from Alpha DNA,Canada.
The PCR mix was with a magnesium concentration of 2 mM being preferred for the erm (B) primer set and 4 mM for the mef (E) primer set. Electrophoresis on 1% agarose gels in 40 mM Tris acetate-2 mM EDTA buffer was used to distinguish PCR products. The size of each PCR product was estimated using standard molecular weight markers (Super DNA Ladder -Low100-bp, Abgene,UK).
RESULTS
Macrolide resist-ance was found in 150 strains (36.3%) out of all 413 tested S. pneumoniae. The invasive isolates of all ERSP from blood, cerebrospinal fluids, ear fluids and excudates were 25 (16.67%).
We observed 87.34% penicillin resistance (Pen-R) and intermediate penicillin resistance (Pen-I) among erythromycinresistant pneumococcus. Of these Pen-R and -I isolates 71.0 % were with MLSB type. Resistant to clindamycin were more than a half (62%) or 93 strains of all ERSP isolates.
The most prevalence of macrolide resistant pneumococci we observed in children under 5 years old -120 patients (80.0%). In this age group 32.5% showed M phenotype and 67.5% of erythromycin-resistant S.pneumoniae were with MLSB phenotype. The patients over 65 years old with infections, caused by ERSP were 17 (11.33%) and these between 18-65 years old were 13 (8.67%).
Macrolide resistance phenotypes
Resistance phenotypes that were determined by triple disk susceptibility method with erythromycin, clindamycin and rokitamycin, showed presence of iMcLS phenotype -86 (57.33%) of all macrolide-resistant isolates, cMLS phenotype showed 16 (10.67%), four were with iMLS phenotype (2.67%) and 44 (29.33%) with M phenotype. (Tabl.1)
Macrolide resistance genotypes Two different molecular genetic mechanisms of macrolide resistance have been described among pneumococci: targed alteration in a result of methylase expression and erythromycin active cell efflux, encoded by erm (Â) and mef (Å) genes.
PCR analysis of the 150 macrolide-resistant pneumococcal isolates showed that 64.7% isolates harboured only the erm (B) gene and 29.3% only the mef (Å) gene. Nine (6.0%) isolates carried both erm (B) and mef (Å) gene. Erm (B)-positive isolates generally had higher MICs for erythromycin and clindamycin, while mef (E)-positive isolates had lower erythromycin MICs and remained susceptible to clindamycin. According to specimen type, erythromycin resistance was found in 22.97% of isolates from sputum or the lower respiratory tract (of which 52.93% were erm (B)-positive, 29.41% were mef (Å) positive, and 17.66 % carried both erm (B) + mef (Å). Macrolide resistance was found in 6.25% of isolates from blood (all mef (Å) -positive), in 15 % of isolates from cerebrospinal fluid (all erm (B)-positive), in 25 % from sinus pus (of which 50% were erm (B)-positive and 50% carried both erm (B) + mef (Å). Resistant to erythromycin were 25% from eye fluids isolates (all erm (B)-positive). We observe prevalence again for erm (B) gene in 41.4% of isolates from nose or throat samples.
Of S. pneumoniae isolates from middle ear fluid samples, 61.3% were erythromycin-resistant and the distribution rates were: erm(B)-positive were 84.21%, mef (Å) posistive were 10.53% and only 5.26% were positive both to erm (B) and mef (Å).
Although 80% of erythromycin-resistant isolates were from children aged < 5 years, only 32.5% were mef (E)-positive isolates from this age group. Erm (B)-positive isolates were 60.83% of erythromycin-resistant isolates in this group and only 8 (6.67%) carried both erm (B) and mef (Å) genes.
These data suggest a link between high macrolide consumption and the selection of erm (B)-positive rather than mef (E)-positive strains.
Serotyping. A total of 109 strains of all 150 ERSP strains were tested up to now. ERSP serotypes/serogroups that we observed were: Serogroup 6-31.19%, Serogroup 19 -49.54%, Serotype 14 -19.27%. Further analysis of serotyping were with factor specific antisera. Serotypes 6Â, 19F and 19A were the most prevalent among ERSP with erm
